Last reviewed · How we verify
Placebo and Triamcinolone ointment
Triamcinolone is a topical corticosteroid that reduces inflammation and immune response in skin conditions by suppressing inflammatory mediators and immune cell activity.
Triamcinolone is a topical corticosteroid that reduces inflammation and immune response in skin conditions by suppressing inflammatory mediators and immune cell activity. Used for Inflammatory and pruritic dermatological conditions (e.g., eczema, psoriasis, dermatitis).
At a glance
| Generic name | Placebo and Triamcinolone ointment |
|---|---|
| Sponsor | All India Institute of Medical Sciences, Bhubaneswar |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Triamcinolone acetonide is a synthetic glucocorticoid that binds to glucocorticoid receptors in the skin, suppressing the production of inflammatory cytokines and reducing vasodilation, edema, and immune cell infiltration. The placebo component serves as a control in this formulation. When applied topically as an ointment, it provides anti-inflammatory, antipruritic, and vasoconstrictive effects localized to the affected skin area.
Approved indications
- Inflammatory and pruritic dermatological conditions (e.g., eczema, psoriasis, dermatitis)
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Local irritation or burning
- Systemic corticosteroid absorption (with prolonged use)
Key clinical trials
- A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (PHASE3)
- Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus (PHASE4)
- Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis (PHASE3)
- Tacrolimus Ointment in Oral Lichen Planus (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: